G-CON inks contract with GenCure for new biomanufacturing facility

By Murielle Gonzalez | Published: 29-Mar-2019

Company in the VelocityTX innovation centre has chosen cleanroom PODs to support cell therapy trials

GenCure, a cell-based therapies specialist based in San Antonio, Texas (US), has selected G-CON Manufacturing for its new multi-product cell therapy facility at the VelocityTX innovation centre.

The project will see G-CON build a biomanufacturing site that will serve as the anchor for the VelocityTX innovation centre in San Antonio. The site will expand GenCure’s manufacturing capabilities to support clinical cell therapy trials.

The PODs will provide approximately 6,700 sqft of cleanroom space to facilitate production of the large numbers of consistent, high-quality, clinical-grade adult stem cells needed to help bring potential new therapies into human clinical trials.

“We are very excited and grateful for the opportunity to design and build PODs for this important project at GenCure,” said Peter Makowenskyj, Director of Sales Engineering at G-CON Manufacturing.

“Cell therapies can successfully treat previously unmet medical needs and for that reason are one of the fastest growing segments in our industry. Based on our experience in this space, G-CON is well prepared to support GenCure’s needs by providing the fastest and most flexible technology available in the cleanroom market.

The site has been designed to facilitate the future expansion of up to 14,000 sqft of cleanroom capacity. Being prefabricated and largely autonomous, PODs are ideal for the planned expansion phases while avoiding impact to ongoing manufacturing, G-CON said.

“There is a pent-up demand for stem cells needed to bring potential new cellular therapies into clinical trials, and the major bottleneck in the system is a lack of biomanufacturing capacity,” said Becky Cap, Senior Vice President of BioBridge Global and Chief Operating Officer for GenCure.

“An important benefit of G-CON’s prefabricated modular cleanroom system is that it will speed up the design, build and validation process for our production facilities, supporting our goal of bringing the first phase of this new biomanufacturing space online by the end of the year.”

GenCure is a subsidiary of BioBridge Global, a family of non-profits that oversees and supports the South Texas Blood & Tissue Center, QualTex Laboratories, GenCure, and The Blood and Tissue Center Foundation.

You may also like